We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Immunicum AB (IMMU) NPV

Sell:0.47 SEK Buy:0.47 SEK Change: 0.02 SEK (4.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:0.47 SEK
Buy:0.47 SEK
Change: 0.02 SEK (4.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:0.47 SEK
Buy:0.47 SEK
Change: 0.02 SEK (4.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Contact details

Address:
Ostermalmstorg 5
STOCKHOLM
111 53
Sweden
Telephone:
+46 (8) 7328400
Website:
https://mendus.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMMU
ISIN:
SE0005003654
Market cap:
493.52 million SEK
Shares in issue:
863.15 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Erik Manting
    Chief Executive Officer
  • Lotta Ferm
    Chief Financial Officer
  • Leopold Bertea
    Chief Technology Officer
  • Alex Karlsson-Parra
    Chief Scientific Officer
  • Jeroen Rovers
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.